Sunshine Insurance took part in the eye-focused gene therapy developer's series C round, which pushed its overall funding past $140m.

China-based ophthalmic gene therapy developer Neurophth Therapeutics received over $60m yesterday in a series C round featuring funds and accounts managed by insurance provider Sunshine Insurance.

Venture capital firm Sequoia Capital China and investment manager CMG-SDIC Capital co-led the round, which included funds and accounts managed by China Merchant Bank International Capital.

Founded in 2016, Neurophth is developing gene therapies for diseases affecting the eyes, such as Leber hereditary optic neuropathy (LHON), glaucoma, autosomal dominant optic atrophy.

The series C…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn